Document is current
Any future updates will be listed below
-
Authors
Nuruzzaman, Farzana https://orcid.org/0000-0002-2660-019X
Sato, T. Shawn https://orcid.org/0000-0002-3082-3070
Stimec, Jennifer https://orcid.org/0000-0002-3091-532X
Iyer, Ramesh S.
Carbert, Andrew
Paschke, Joel
Potts, Lauren
Beer, Meinrad https://orcid.org/0000-0001-7523-1979
Huang, Ming
Monsalve, Johanna
Ngo, Anh-Vu
Thapa, Mahesh
Zhang, Xiaoyue
Maksymowych, Walter P. https://orcid.org/0000-0002-1291-1755
Ferguson, Polly J. https://orcid.org/0000-0002-9901-0334
Zhao, Yongdong https://orcid.org/0000-0003-3618-1379
,
-
Funding
Funding for this research was provided by:
CARRA-Arthritis Foundation (92240)
- License Information
-
More Information
Article History
Received: 13 January 2025
Accepted: 16 July 2025
First Online: 1 August 2025
Declarations
:
: This project was approved by Stony Brook University Hospital# IRB2021-00033, and institutional review board from Iowa Children’s Hospital (# 201609778) and Seattle Children’s Hospital (#2683). We agree to the integrity of this work and agree to bear the applicable publication charges if our manuscript is accepted for publication. The content of the full-length manuscript has not been published elsewhere.
: Not applicable.
: WPM: Chief Medical Officer, CARE Arthritis Limited, Edmonton, Canada. Grant/research support from AbbVie, BMS, Galapagos, Novartis, Pfizer and UCB Pharma; consulting fees, speaking fees and/or honoraria fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli-Lilly, Medscape, Novartis, Peervoice, Pfizer and UCB Pharma; Editorial Board member Journal of Rheumatology, RMD Open, Clinical and Experimental Rheumatology; and royalties or licences from the University of British Columbia for the 14-3-3eta diagnostic biomarker. •YZ: Grant/research support from CARRA Arthritis Foundation, Bristol-Myer Squibbs, Rheumatology Research Foundation, CTIP, Kaila’s Komfort, NIH NIAMS 1R56AR083929-01; Royalties from UpToDate; member of Pediatric Rheumatology Subboard.
